medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 1

<< Back Next >>

Med Int Mex 2018; 34 (1)

Guillain-Barre syndrome: older and news concepts

Rebolledo-García D, González-Vargas PO, Salgado-Calderón I

Language: Spanish
References: 31
Page: 72-81
PDF size: 396.33 Kb.


ABSTRACT

Currently, Guillain-Barre syndrome (GBS) is the most frequent cause of acute flaccid paralysis. The classical form of syndrome has not undergone major changes in their clinical behavior; however, the spectrum of clinical variants of the syndrome is extensive, supporting advances in molecular biology and immunology have allowed better characterize these forms of GBS. The anti-ganglioside antibodies have restructured the criteria because they increase the sensitivity and specificity of diagnosis; because of this, the traditional criteria are inadequate for appropriated classification and discriminate imitators of the syndrome. The evolution of the criteria should change the perspective in addressing the box and regulate the therapeutic approach, without exceeding the clinical trial of daily medical practice.


REFERENCES

  1. Clifford R. History of British Neurology. 1a ed. Imperial College Press; 2012.

  2. Guillain Barré & Associated Inflammatory Neuropathies, 2010. (Accesed 28 diciembre, 2015 at http://www.gaincharity. org.uk/history-of-gbs/info_71.html).

  3. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7:939-50.

  4. García Ramos GS, Cacho Díaz B. Síndrome de Guillain- Barré (SGB). Diagnóstico diferencial. Rev Mex Neuroci 2005;6(5):448-454.

  5. McGrogan A, Gemma C, MHelen, Seaman ME. The epidemiology of Guillain-Barré syndrome worldwide. Neuroepidemiology 2009;32:150-163.

  6. James J, Sejvar ALS, Matthew WB, et al. Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology 2011 36:123-133.

  7. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304.

  8. Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 1995 Jun;118 (Pt 3):577-95.

  9. Rees JH, Soudain S, etal. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-9.

  10. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-1136.

  11. Lunn M, Hughes R. The relationship between Cytomegalovirus infection and Guillain-Barré syndrome. Clin Infect Dis 2011 ;52(7):845-847.

  12. Domínguez-Moreno R, Tolosa-Tort P, Patiño-Tamez A, Quintero-Bauman A y col. Mortalidad asociada al diagnóstico de síndrome de Guillain-Barré en adultos ingresados en instituciones del sistema sanitario mexicano. Rev Neurol 2014;58(1):4-10.

  13. Yu RK, Tsai YT, et al. Structures, biosynthesis, and functions of gangliosides—An overview. J Oleo Sci 2011;60(10):537-544.

  14. Yuki N. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist’s journey. Proc Jpn Acad Ser B Phys Biol Sci 2012;88:299-326.

  15. Wim AC, Jacobs BC, Laman JD. The Guillain-Barre’ syndrome: a true case of molecular mimicry. Trends in Immunol 2004;25:1-6.

  16. Osler LD, Sidell AD. The Guillain-Barré syndrome—The need for exact diagnostic criteria. N Engl J Med 1960;262:964-969.

  17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27 Suppl:S21-4.

  18. Fokke C, Van den Berg B, et al. Diagnosis of Guillain- Barré syndrome and validation of Brighton criteria. Brain 2014;(33)137:33-43.

  19. Wakerley BR, Uncini A, Yuki N, et al. Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. Nat Rev Neurol 2014;10:537-544.

  20. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010;(6):CD002063.

  21. Vucic S, Kiernan MC. Guillain-Barre syndrome: An update. J Clin Neurosci 2009. DOI: 10.1016/j.jocn.2008.08.033

  22. Yuki N. Relation between critical illness polyneuropathy and axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1999;67:121-133.

  23. Walgaard C, Lingsma HF, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011 Mar 15;76(11):968-975.

  24. van Koningsveld R, Steyerberg EW, Hughes RA. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 2007 Jul;6(7):589-94.

  25. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-66.

  26. Wöhrle JC; Spengos K. Alcohol-related acute axonal polyneuropathy: A differential diagnosis of Guillain-Barré syndrome. Arch Neurol 1998;55(10):1329-1334.

  27. Martens-Le Bouar H, Korinthenberg R. Polyradiculoneuritis with myelitis: a rare differential diagnosis of Guillain-Barre syndrome. Neuropediatrics 2002;33(2):93-96.

  28. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010;74(21):1680.

  29. Hughes RA, Wijdicks FM, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62(8):1194-1198.

  30. Hughes RA, Wijdicks FM, et al. Practice parameter: Immunotherapy for Guillain–Barré syndrome. Neurology 2003;61:736-740.

  31. Willison HJ, Jacobs BC, Doorn PA. Guillain-Barré syndrome. Lancet Seminar 2016: http://dx.doi.org/10.1016/S0140- 6736(16)00339-1.




2020     |     www.medigraphic.com